Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Immunome, Inc. (NASDAQ: IMNM)
IMNM Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
182.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
73.10%
IMNM Stock Analysis
IMNM
PE Ratio:
IMNM
PEG Ratio:
Not Available
IMNM
Forward EPS Growth (12 month):
0.00%
IMNM
PS Ratio:
471.7
IMNM
PSG Ratio:
1.2
IMNM
Forward Revenue Growth (12 month):
400.00%
IMNM Articles
No data was found